Compare AbbVie Inc (ABBV) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Bitwise Crypto Industry Innovators ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Bitwise Crypto Industry Innovators ETF trades at $23.42. The key difference: AbbVie Inc pays a 2.72% dividend while Bitwise Crypto Industry Innovators ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | BITQ | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Crypto-linked |
52-Week High | $261.07 | $30.43 |
52-Week Low | $184.85 | $16.74 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
BITQ trades at $24.83, up 4.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is firm near $24, while resistance sits at $25-$26. The ETF's performance remains tied to crypto industry sentiment, with recent news highlighting investor outflows from Bitcoin ETFs amid market volatility. Financial ratios are unavailable, limiting fundamental clarity.
Outlook is cautious due to bearish technicals and sector headwinds. Opportunities exist if crypto markets rebound, but risks include regulatory uncertainty and reliance on volatile underlying assets. Investors should monitor ETF inflows and broader crypto adoption trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
